Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies

Blood Reviews

Volumn 30, Issue 4, 2016, Pages 245-256

  Noubouossie, Denis ^a   Key, Nigel S ^a   Ataga, Kenneth I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation activation; Complications; Hemolysis; Inflammation; Platelet activation; Sickle cell disease

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 8; D DIMER; EPTIFIBATIDE; FIBRINOPEPTIDE A; HYDROXYUREA; NITRIC OXIDE; PHOSPHATIDYLSERINE; PLASMIN; PLASMIN ANTIPLASMIN COMPLEX; PRASUGREL; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN FRAGMENT 1.2; RIVAROXABAN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TICLOPIDINE; TINZAPARIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE CHEST SYNDROME; ALBUMINURIA; AVASCULAR NECROSIS; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CHRONIC BLOOD TRANSFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ERYTHROCYTE; EX VIVO STUDY; HEMOLYSIS; HUMAN; IN VIVO STUDY; INFLAMMATION; LIMIT OF QUANTITATION; MEMBRANE MICROPARTICLE; MULTICENTER STUDY (TOPIC); NONHUMAN; PAIN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REPERFUSION INJURY; RETROSPECTIVE STUDY; REVIEW; SICKLE CELL ANEMIA; SILENT CEREBRAL INFARCT; THROMBOCYTE ACTIVATION; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPHY; TREATMENT DURATION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; BLOOD COAGULATION; HUMANS; TREATMENT OUTCOME;

EID: 84954271658     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.12.003     Document Type: Review

References (201)

1. [1] Piel, F.B., Patil, A.P., Howes, R.E., Nyangiri, O.A., Gething, P.W., Dewi, M., et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 381 (2013), 142–151.
2. [2] Piel, F.B., Hay, S.I., Gupta, S., Weatherall, D.J., Williams, T.N., Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med, 10, 2013, e1001484.
3. [3] Chakravorty, S., Williams, T.N., Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child 100 (2015), 48–53.
4. [4] Ohene-Frempong, K., Weiner, S.J., Sleeper, L.A., Miller, S.T., Embury, S., Moohr, J.W., et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91 (1998), 288–294.
5. [5] Stein, P.D., Beemath, A., Meyers, F.A., Skaf, E., Olson, R.E., Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 119:897 (2006), e7–11.
6. [6] Novelli, E.M., Huynh, C., Gladwin, M.T., Moore, C.G., Ragni, M.V., Pulmonary embolism in sickle cell disease: a case–control study. J Thromb Haemost 10 (2012), 760–766.
7. [7] Naik, R.P., Streiff, M.B., Haywood, C., Nelson, J.A., Lanzkron, S., Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med 126 (2013), 443–449.
8. [8] Naik, R.P., Streiff, M.B., Haywood, C., Segal, J.B., Lanzkron, S., Venous thromboembolism incidence in the cooperative study of sickle cell disease. J Thromb Haemost 12 (2014), 2010–2016.
9. [9] Ataga, K.I., Key, N.S., Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematol Am Soc Hematol Educ Program, 91–6, 2007.
10. [10] De Franceschi, L., Cappellini, M.D., Olivieri, O., Thrombosis and sickle cell disease. Semin Thromb Hemost 37 (2011), 226–236.
11. [11] Rahimi, Z., Parsian, A., Sickle cell disease and venous thromboembolism. Mediterr J Hematol Infect Dis, 3, 2011, e2011024.
12. [12] Lim, M.Y., Ataga, K.I., Key, N.S., Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 20 (2013), 472–477.
13. [13] Pakbaz, Z., Wun, T., Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematol Oncol Clin North Am 28 (2014), 355–374.
14. [14] Nsiri, B., Gritli, N., Bayoudh, F., Messaoud, T., Fattoum, S., Machghoul, S., Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Hematol Cell Ther 38 (1996), 279–284.
15. [15] Westerman, M.P., Green, D., Gilman-Sachs, A., Beaman, K., Freels, S., Boggio, L., et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 134 (1999), 352–362.
16. [16] Hagger, D., Wolff, S., Owen, J., Samson, D., Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis Int J Haemost Thromb 6 (1995), 93–99.
17. [17] Peters, M., Plaat, B.E., ten Cate, H., Wolters, H.J., Weening, R.S., Brandjes, D.P., Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 71 (1994), 169–172.
18. [18] Kurantsin-Mills, J., Ofosu, F.A., Safa, T.K., Siegel, R.S., Lessin, L.S., Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 81 (1992), 539–544.
19. [19] Setty, B.N., Rao, A.K., Stuart, M.J., Thrombophilia in sickle cell disease: the red cell connection. Blood 98 (2001), 3228–3233.
20. [20] Key, N.S., Slungaard, A., Dandelet, L., Nelson, S.C., Moertel, C., Styles, L.A., et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 91 (1998), 4216–4223.
21. [21] Liesner, R., Mackie, I., Cookson, J., McDonald, S., Chitolie, A., Donohoe, S., et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol 103 (1998), 1037–1044.
22. [22] Tomer, A., Harker, L.A., Kasey, S., Eckman, J.R., Thrombogenesis in sickle cell disease. J Lab Clin Med 137 (2001), 398–407.
23. [23] Colombatti, R., De Bon, E., Bertomoro, A., Casonato, A., Pontara, E., Omenetto, E., et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One, 8, 2013, e78801.
24. [24] Ataga, K.I., Brittain, J.E., Desai, P., May, R., Jones, S., Delaney, J., et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One, 7, 2012, e29786.
25. [25] Hemker, H.C., Giesen, P., AlDieri, R., Regnault, V., de Smed, E., Wagenvoord, R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32 (2002), 249–253.
26. [26] Hemker, H.C., Al Dieri, R., De Smedt, E., Béguin, S., Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96 (2006), 553–561.
27. [27] Hemker, H.C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003), 4–15.
28. [28] Ninivaggi, M., Apitz-Castro, R., Dargaud, Y., de Laat, B., Hemker, H.C., Lindhout, T., Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 58 (2012), 1252–1259.
29. [29] Amin, C., Adam, S., Mooberry, M.J., Kutlar, A., Kutlar, F., Esserman, D., et al. Coagulation activation in sickle cell trait: an exploratory study. Br J Haematol 171 (2015), 638–646.
30. [30] Shah, N., Thornburg, C., Telen, M.J., Ortel, T.L., Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res 130 (2012), e241–e245.
31. [31] Gerotziafas, G.T., Van Dreden, P., Chaari, M., Galea, V., Khaterchi, A., Lionnet, F., et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 107 (2012), 1044–1052.
32. [32] Noubouossie, D.F., Lê, P.Q., Corazza, F., Debaugnies, F., Rozen, L., Ferster, A., et al. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol 87 (2012), 145–149.
33. [33] Dargaud, Y., Luddington, R., Gray, E., Negrier, C., Lecompte, T., Petros, S., et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 139 (2007), 303–309.
34. [34] Whelihan, M.F., Lim, M.Y., Walton, B.L., Wolberg, A.S., Cai, J., Ataga, K.I., et al. Hypercoagulability in sickle cell disease: the importance of the cellular component of blood. Blood, 124, 2014, 4060-4060.
35. [35] Yee, D.L., Edwards, R.M., Mueller, B.U., Teruya, J., Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease. Arch Pathol Lab Med 129 (2005), 760–765.
36. [36] Setty, B.N.Y., Key, N.S., Rao, A.K., Gayen-Betal, S., Krishnan, S., Dampier, C.D., et al. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol 157 (2012), 370–380.
37. [37] Solovey, A., Gui, L., Key, N.S., Hebbel, R.P., Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 101 (1998), 1899–1904.
38. [38] Shet, A.S., Aras, O., Gupta, K., Hass, M.J., Rausch, D.J., Saba, N., et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102 (2003), 2678–2683.
39. [39] van Beers, E.J., Spronk, H.M.H., Ten Cate, H., Duits, A.J., Brandjes, D.P.M., van Esser, J.W.J., et al. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica 93 (2008), e42–e44.
40. [40] Ataga, K.I., Moore, C.G., Hillery, C.A., Jones, S., Whinna, H.C., Strayhorn, D., et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 93 (2008), 20–26.
41. [41] Setty, B.N.Y., Betal, S.G., Zhang, J., Stuart, M.J., Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 6 (2008), 2202–2209.
42. [42] Rehani, T., Mathson, K., Belcher, J.D., Vercellotti, G.M., Heme potently stimulates tissue factor expression by peripheral blood monocytes: a novel mechanism for thrombosis in intravascular hemolytic diseases. Blood, 122, 2013, 2215-2215.
43. [43] Sparkenbaugh, E.M., Chantrathammachart, P., Wang, S., Jonas, W., Kirchhofer, D., Gailani, D., et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica 100 (2015), 308–314.
44. [44] Solovey, A., Kollander, R., Milbauer, L.C., Abdulla, F., Chen, Y., Kelm, R.J., et al. Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. Am J Hematol 85 (2010), 41–45.
45. [45] Solovey, A., Kollander, R., Shet, A., Milbauer, L.C., Choong, S., Panoskaltsis-Mortari, A., et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 104 (2004), 840–846.
46. [46] Aufradet, E., DeSouza, G., Bourgeaux, V., Bessaad, A., Campion, Y., Canet-Soulas, E., et al. Hypoxia/reoxygenation stress increases markers of vaso-occlusive crisis in sickle SAD mice. Clin Hemorheol Microcirc 54 (2013), 297–312.
47. [47] Kollander, R., Solovey, A., Milbauer, L.C., Abdulla, F., Kelm, R.J., Hebbel, R.P., Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Transl Res J Lab Clin Med 155 (2010), 170–177.
48. [48] Gavins, F.N.E., Russell, J., Senchenkova, E.L., De Almeida, P.L., Damazo, A.S., Esmon, C.T., et al. Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood 117 (2011), 4125–4133.
49. [49] Chantrathammachart, P., Mackman, N., Sparkenbaugh, E., Wang, J.-G., Parise, L.V., Kirchhofer, D., et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood 120 (2012), 636–646.
50. [50] Gordon, E.M., Klein, B.L., Berman, B.W., Strandjord, S.E., Simon, J.E., Coccia, P.F., Reduction of contact factors in sickle cell disease. J Pediatr 106 (1985), 427–430.
51. [51] Verma, P.S., Adams, R.G., Miller, R.L., Reduced plasma kininogen concentration during sickle cell crisis. Res Commun Chem Pathol Pharmacol 41 (1983), 313–322.
52. [52] Miller, R.L., Verma, P.S., Adams, R.G., Studies of the kallikrein-kinin system in patients with sickle cell anemia. J Natl Med Assoc 75 (1983), 551–556.
53. [53] Smith, S.A., Travers, R.J., Morrissey, J.H., How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol 28 (2015), 1–11.
54. [54] Wu, Y., Contact pathway of coagulation and inflammation. Thromb J, 13, 2015, 17.
55. [55] Morrissey, J.H., Choi, S.H., Smith, S.A., Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 119 (2012), 5972–5979.
56. [56] Al-Humood, S., Zueriq, R., Al-Faris, L., Marouf, R., Al-Mulla, F., Circulating cell-free DNA in sickle cell disease: is it a potentially useful biomarker?. Arch Pathol Lab Med 138 (2014), 678–683.
57. [57] Vasavda, N., Ulug, P., Kondaveeti, S., Ramasamy, K., Sugai, T., Cheung, G., et al. Circulating DNA: a potential marker of sickle cell crisis. Br J Haematol 139 (2007), 331–336.
58. [58] Schimmel, M., Nur, E., Biemond, B.J., van Mierlo, G.J., Solati, S., Brandjes, D.P., et al. Nucleosomes and neutrophil activation in sickle cell disease painful crisis. Haematologica 98 (2013), 1797–1803.
59. [59] Sparkenbaugh, E., Key, N.S., Chandarajoti, K., Gruber, A., Mackman, N., McCrae, K., et al. Kininogen deficiency attenuates thrombin generation in a mouse model of sickle cell disease (ISTH Abstract). J Thromb Haemost, 13(S2), 2015, 17.
60. [60] Lee, S.P., Ataga, K.I., Orringer, E.P., Phillips, D.R., Parise, L.V., Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 26 (2006), 1626–1631.
61. [61] Jakubowski, J.A., Zhou, C., Jurcevic, S., Winters, K.J., Lachno, D.R., Frelinger, A.L., et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res 133 (2014), 190–195.
62. [62] Famodu, A.A., Oduwa, D., Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Br J Biomed Sci 52 (1995), 323–324.
63. [63] Westwick, J., Watson-Williams, E.J., Krishnamurthi, S., Marks, G., Ellis, V., Scully, M.F., et al. Platelet activation during steady state sickle cell disease. J Med 14 (1983), 17–36.
64. [64] Papadimitriou, C.A., Travlou, A., Kalos, A., Douratsos, D., Lali, P., Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis. Acta Haematol 89 (1993), 180–183.
65. [65] Browne, P.V., Mosher, D.F., Steinberg, M.H., Hebbel, R.P., Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51 (1996), 296–301.
66. [66] Wun, T., Paglieroni, T., Rangaswami, A., Franklin, P.H., Welborn, J., Cheung, A., et al. Platelet activation in patients with sickle cell disease. Br J Haematol 100 (1998), 741–749.
67. [67] Proença-Ferreira, R., Franco-Penteado, C.F., Traina, F., Saad, S.T.O., Costa, F.F., Conran, N., Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. Br J Haematol 149 (2010), 280–288.
68. [68] Westwick, J., Watson-Williams, E.J., Krishnamurthi, S., Marks, G., Ellis, V., Scully, M.F., et al. Platelet activation during steady state sickle cell disease. J Med 14 (1983), 17–36.
69. [69] Wun, T., Paglieroni, T., Tablin, F., Welborn, J., Nelson, K., Cheung, A., Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 129 (1997), 507–516.
70. [70] Kenny, M.W., George, A.J., Stuart, J., Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 33 (1980), 622–625.
71. [71] Mehta, P., Mehta, J., Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 96 (1980), 209–213.
72. [72] Stuart, M.J., Stockman, J.A., Oski, F.A., Abnormalities of platelet aggregation in the vaso-occlusive crisis of sickle-cell anemia. J Pediatr 85 (1974), 629–632.
73. [73] Brousse, V., Buffet, P., Rees, D., The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol 166 (2014), 165–176.
74. [74] Villagra, J., Shiva, S., Hunter, L.A., Machado, R.F., Gladwin, M.T., Kato, G.J., Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110 (2007), 2166–2172.
75. [75] Wood, B.L., Gibson, D.F., Tait, J.F., Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 88 (1996), 1873–1880.
76. [76] Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratton, D.L., Henson, P.M., Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol Baltim Md 1950 148 (1992), 2207–2216.
77. [77] McEvoy, L., Williamson, P., Schlegel, R.A., Membrane phospholipid asymmetry as a determinant of erythrocyte recognition by macrophages. Proc Natl Acad Sci U S A 83 (1986), 3311–3315.
78. [78] Schroit, A.J., Madsen, J.W., Tanaka, Y., In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 260 (1985), 5131–5138.
79. [79] Westerman, M., Pizzey, A., Hirschman, J., Cerino, M., Weil-Weiner, Y., Ramotar, P., et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 142 (2008), 126–135.
80. [80] Whelihan, M.F., Mooberry, M.J., Zachary, V., Bradford, R.L., Ataga, K.I., Mann, K.G., et al. The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb Haemost 11 (2013), 2187–2189.
81. [81] Zwaal, R.F., Schroit, A.J., Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89 (1997), 1121–1132.
82. [82] Whelihan, M.F., Zachary, V., Orfeo, T., Mann, K.G., Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood 120 (2012), 3837–3845.
83. [83] Setty, B.N., Kulkarni, S., Rao, A.K., Stuart, M.J., Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 96 (2000), 1119–1124.
84. [84] Bezeaud, A., Venisse, L., Helley, D., Trichet, C., Girot, R., Guillin, M.-C., Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C. Br J Haematol 117 (2002), 409–413.
85. [85] Connor, D.E., Exner, T., Ma, D.D.F., Joseph, J.E., Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT. Blood Coagul Fibrinolysis Int J Haemost Thromb 20 (2009), 558–564.
86. [86] Marco, A., Brocal, C., Marco, P., Measurement of procoagulant activity of microparticles in plasma: feasibility of new functional assays. Thromb Res 134 (2014), 1363–1364.
87. [87] van Beers, E.J., Schaap, M.C.L., Berckmans, R.J., Nieuwland, R., Sturk, A., van Doormaal, F.F., et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 94 (2009), 1513–1519.
88. [88] Noubouossie, D.C.F., Lê, P.-Q., Rozen, L., Debaugnies, F., Ferster, A., Demulder, A., Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res 130 (2012), 259–264.
89. [89] van Tits, L.J., van Heerde, W.L., Landburg, P.P., Boderie, M.J., Muskiet, F.a., Jacobs N, J., et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun 390 (2009), 161–164.
90. [90] Van Der Meijden, P.E.J., Van Schilfgaarde, M., Van Oerle, R., Renné, T., Ten Cate, H., Spronk, H.M.H., Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa: microparticle-driven thrombin generation. J Thromb Haemost 10 (2012), 1355–1362.
91. [91] Yang, A., Colman, R., Wu, Y., Coagulation factor XII binding to apoptotic cells initiates thrombin generation (ISTH abstract). J Thromb Haemost, 13(Suppl. 2), 2015, 231.
92. [92] Kasar, M., Boğa, C., Yeral, M., Asma, S., Kozanoglu, I., Ozdogu, H., Clinical significance of circulating blood and endothelial cell microparticles in sickle-cell disease. J Thromb Thrombolysis 38 (2013), 167–175.
93. [93] Nebor, D., Bowers, A., Connes, P., Hardy-Dessources, M.-D., Knight-Madden, J., Cumming, V., et al. Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia. PLoS One, 9, 2014, e87243.
94. [94] Bayazit, A.K., Kilinç, Y., Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int Off J Jpn Pediatr Soc 43 (2001), 592–596.
95. [95] Noubouossie, D., Lê, P.Q., Rozen, L., Willems, D., Ngalula Mujinga, M., Ferster, A., et al. Factor VIII level correlates with hemolysis and may contribute to the hypercoagulability of children with sickle cell disease (ISTH abstract). J Thromb Haemost, 11(Suppl. 2), 2013, 710.
96. [96] Leslie, J., Langler, D., Serjeant, G.R., Serjeant, B.E., Desai, P., Gordon, Y.B., Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol 30 (1975), 159–166.
97. [97] Babiker, M.A., Ashong, E.F., Bahakim, H., Gader, A.M., Coagulation changes in sickle cell disease in early childhood. Acta Haematol 77 (1987), 156–160.
98. [98] Zhou, Z., Han, H., Cruz, M.A., López, J.A., Dong, J.-F., Guchhait, P., Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101 (2009), 1070–1077.
99. [99] Novelli, E.M., Kato, G.J., Hildesheim, M.E., Barge, S., Meyer, M.P., Lozier, J., et al. Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica 98 (2013), e132–e134.
100. [100] Schnog, J.-J.B., Kremer Hovinga, J.A., Krieg, S., Akin, S., Lämmle, B., Brandjes, D.P.M., et al. ADAMTS13 activity in sickle cell disease. Am J Hematol 81 (2006), 492–498.
101. [101] Chen, J., Hobbs, W.E., Le, J., Lenting, P.J., de Groot, P.G., López, J.A., The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood 117 (2011), 3680–3683.
102. [102] Krishnan, S., Siegel, J., Pullen, G., Hevelow, M., Dampier, C., Stuart, M., Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res 122 (2008), 455–458.
103. [103] el-Hazmi, M.A., Warsy, A.S., Bahakim, H., Blood proteins C and S in sickle cell disease. Acta Haematol 90 (1993), 114–119.
104. [104] Wright, J.G., Malia, R., Cooper, P., Thomas, P., Preston, F.E., Serjeant, G.R., Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels?. Br J Haematol 98 (1997), 627–631.
105. [105] McDonald, J.F., Shah, A.M., Schwalbe, R.A., Kisiel, W., Dahlbäck, B., Nelsestuen, G.L., Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry (Mosc) 36 (1997), 5120–5127.
106. [106] Schwalbe, R.A., Ryan, J., Stern, D.M., Kisiel, W., Dahlbäck, B., Nelsestuen, G.L., Protein structural requirements and properties of membrane binding by gamma-carboxyglutamic acid-containing plasma proteins and peptides. J Biol Chem 264 (1989), 20288–20296.
107. [107] Lane, P.A., O'Connell, J.L., Marlar, R.A., Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S. Am J Hematol 47 (1994), 295–300.
108. [108] Webb, J.H., Blom, A.M., Dahlbäck, B., Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 169 (2002), 2580–2586.
109. [109] Stuart, M.J., Setty, B.N., Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 20 (2001), 27–46.
110. [110] Onyemelukwe, G.C., Jibril, H.B., Anti-thrombin III deficiency in Nigerian children with sickle cell disease. Possible role in the cerebral syndrome. Trop Geogr Med 44 (1992), 37–41.
111. [111] Porter, J.B., Young, L., Mackie, I.J., Marshall, L., Machin, S.J., Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. Br J Haematol 83 (1993), 459–465.
112. [112] Merkel, K.H., Ginsberg, P.L., Parker, J.C., Post, M.J., Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke J Cereb Circ 9 (1978), 45–52.
113. [113] Rothman, S.M., Fulling, K.H., Nelson, J.S., Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 20 (1986), 684–690.
114. [114] Adedeji, M.O., Cespedes, J., Allen, K., Subramony, C., Hughson, M.D., Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 125 (2001), 1436–1441.
115. [115] Haque, A.K., Gokhale, S., Rampy, B.A., Adegboyega, P., Duarte, A., Saldana, M.J., Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 33 (2002), 1037–1043.
116. [116] Adams, R., McKie, V., Nichols, F., Carl, E., Zhang, D.L., McKie, K., et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 326 (1992), 605–610.
117. [117] Verlhac, S., Balandra, S., Cussenot, I., Kasbi, F., Vasile, M., Kheniche, A., et al. Extracranial carotid arteriopathy in stroke-free children with sickle cell anemia: detection by submandibular Doppler sonography. Pediatr Radiol 44 (2014), 587–596.
118. [118] Deane, C.R., Goss, D., Bartram, J., Pohl, K.R.E., Height, S.E., Sibtain, N., et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica 95 (2010), 1287–1292.
119. [119] Telfer, P.T., Evanson, J., Butler, P., Hemmaway, C., Abdulla, C., Gadong, N., et al. Cervical carotid artery disease in sickle cell anemia: clinical and radiological features. Blood 118 (2011), 6192–6199.
120. [120] Linguraru, M.G., Pura, J.A., Gladwin, M.T., Koroulakis, A.I., Minniti, C., Machado, R.F., et al. Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease. Pulm Circ 4 (2014), 319–329.
121. [121] Kato, G.J., Hebbel, R.P., Steinberg, M.H., Gladwin, M.T., Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine and new research directions. Am J Hematol 84 (2009), 618–625.
122. [122] Connes, P., Verlhac, S., Bernaudin, F., Advances in understanding the pathogenesis of cerebrovascular vasculopathy in sickle cell anaemia. Br J Haematol 161 (2013), 484–498.
123. [123] Hoppe, C., Klitz, W., Cheng, S., Apple, R., Steiner, L., Robles, L., et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 103 (2004), 2391–2396.
124. [124] Milbauer, L.C., Wei, P., Enenstein, J., Jiang, A., Hillery, C.A., Scott, J.P., et al. Genetic endothelial systems biology of sickle stroke risk. Blood 111 (2008), 3872–3879.
125. [125] Bensinger, T.A., Gillette, P.N., Hemolysis in sickle cell disease. Arch Intern Med 133 (1974), 624–631.
126. [126] Gladwin, M.T., Kato, G.J., Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!. Haematologica 93 (2008), 1–3.
127. [127] Reiter, C.D., Wang, X., Tanus-Santos, J.E., Hogg, N., Cannon, R.O., Schechter, A.N., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8 (2002), 1383–1389.
128. [128] Rezaie, A.R., Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost 112 (2014), 876–882.
129. [129] Chen, D., Ma, L., Tham, E.-L., Maresh, S., Lechler, R.I., McVey, J.H., et al. Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms. J Thromb Haemost 11 (2013), 963–974.
130. [130] Sparkenbaugh, E.M., Chantrathammachart, P., Mickelson, J., van Ryn, J., Hebbel, R.P., Monroe, D.M., et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123 (2014), 1747–1756.
131. [131] James, A.H., Jamison, M.G., Brancazio, L.R., Myers, E.R., Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 194 (2006), 1311–1315.
132. [132] James, A.H., Prevention and treatment of venous thromboembolism in pregnancy. Clin Obstet Gynecol 55 (2012), 774–787.
133. [133] Villers, M.S., Jamison, M.G., De Castro, L.M., James, A.H., Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 199:125 (2008), e1–e5.
134. [134] Heit, J.A., Kobbervig, C.E., James, A.H., Petterson, T.M., Bailey, K.R., Melton, L.J., Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143 (2005), 697–706.
135. [135] Boulet, S.L., Okoroh, E.M., Azonobi, I., Grant, A., Craig, H.W., Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population. Matern Child Health J 17 (2013), 200–207.
136. [136] Seaman, C.D., Yabes, J., Li, J., Moore, C.G., Ragni, M.V., Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis. Thromb Res 134 (2014), 1249–1252.
137. [137] Costa, V.M.F., Viana, M.B., Aguiar, R.A.L.P., Pregnancy in patients with sickle cell disease: maternal and perinatal outcomes. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet 28 (2015), 685–689.
138. [138] Noubouossie, D., Key, N.S., Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. Thromb Res 135:S1 (2015), S46–S48.
139. [139] Manci, E.A., Culberson, D.E., Yang, Y.-M., Gardner, T.M., Powell, R., Haynes, J., et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123 (2003), 359–365.
140. [140] Kirkham, F.J., Hewes, D.K., Prengler, M., Wade, A., Lane, R., Evans, J.P., Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet Lond Engl 357 (2001), 1656–1659.
141. [141] Adams, R.J., Kutlar, A., McKie, V., Carl, E., Nichols, F.T., Liu, J.C., et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol 45 (1994), 279–282.
142. [142] Vi, J.G.T., Tang, D.C., Savage, S.A., Leitman, S.F., Heller, S.I., Serjeant, G.R., et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100 (2002), 4303–4309.
143. [143] Sebastiani, P., Ramoni, M.F., Nolan, V., Baldwin, C.T., Steinberg, M.H., Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 37 (2005), 435–440.
144. [144] Tantawy, A.A.G., Adly, A.A.M., Ismail, E.A.R., Habeeb, N.M., Farouk, A., Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: relation to cardiovascular complications. Platelets 24 (2013), 605–614.
145. [145] Khanduri, U., Gravell, D., Christie, B.S., Al Lamki, Z., Zachariah, M., Cherian, E., Reduced protein C levels—a contributory factor for stroke in sickle cell disease. Thromb Haemost 79 (1998), 879–880.
146. [146] Tam, D.A., Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 12 (1997), 19–21.
147. [147] Noubouossie, D.C.F., Lê, P.Q., Rozen, L., Ziereisen, F., Willems, D., Demulder, A., et al. Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. Eur J Haematol 91 (2013), 46–54.
148. [148] DeBaun, M.R., Armstrong, F.D., McKinstry, R.C., Ware, R.E., Vichinsky, E., Kirkham, F.J., Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 119 (2012), 4587–4596.
149. [149] Quinn, C.T., Breakthrough: new guidance for silent cerebral ischemia and infarction in sickle cell disease. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2014 (2014), 438–443.
150. [150] Schatz, J., Brown, R.T., Pascual, J.M., Hsu, L., DeBaun, M.R., Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 56 (2001), 1109–1111.
151. [151] Vichinsky, E.P., Neumayr, L.D., Earles, A.N., Williams, R., Lennette, E.T., Dean, D., et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 342 (2000), 1855–1865.
152. [152] Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330 (1994), 1639–1644.
153. [153] Manci, E.A., Culberson, D.E., Yang, Y.-M., Gardner, T.M., Powell, R., Haynes, J., et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123 (2003), 359–365.
154. [154] Mekontso Dessap, A., Deux, J.-F., Abidi, N., Lavenu-Bombled, C., Melica, G., Renaud, B., et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 184 (2011), 1022–1029.
155. [155] Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 (2004), 886–895.
156. [156] Ataga, K.I., Moore, C.G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 134 (2006), 109–115.
157. [157] Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:25 Suppl (2013), D42–D50.
158. [158] Milner, P.F., Kraus, A.P., Sebes, J.I., Sleeper, L.A., Dukes, K.A., Embury, S.H., et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 325 (1991), 1476–1481.
159. [159] Glueck, C.J., Freiberg, R.A., Wang, P., Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin Orthop 466 (2008), 1034–1040.
160. [160] Kang, P., Shen, B., Yang, J., Pei, F., Circulating platelet-derived microparticles and endothelium-derived microparticles may be a potential cause of microthrombosis in patients with osteonecrosis of the femoral head. Thromb Res 123 (2008), 367–373.
161. [161] Marsh, A., Schiffelers, R., Kuypers, F., Larkin, S., Gildengorin, G., van Solinge, W., et al. Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease. Br J Haematol 168 (2015), 135–138.
162. [162] Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 332 (1995), 1317–1322.
163. [163] Wang, W.C., Ware, R.E., Miller, S.T., Iyer, R.V., Casella, J.F., Minniti, C.P., et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet Lond Engl 377 (2011), 1663–1672.
164. [164] Zimmerman, S.A., Schultz, W.H., Burgett, S., Mortier, N.A., Ware, R.E., Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 110 (2007), 1043–1047.
165. [165] Kratovil, T., Bulas, D., Driscoll, M.C., Speller-Brown, B., McCarter, R., Minniti, C.P., Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer 47 (2006), 894–900.
166. [166] Lagunju, I., Brown, B.J., Sodeinde, O., Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort. Pediatr Blood Cancer 62 (2015), 1587–1591.
167. [167] de C, L.C.L., JFC, P., Nascimento, E.M., Moura, P.G., Cardoso, G.P., Hankins, J.S., The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 161 (2013), 852–860.
168. [168] Greenway, A., Ware, R.E., Thornburg, C.D., Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol 86 (2011), 357–361.
169. [169] Sumoza, A., de Bisotti, R., Sumoza, D., Fairbanks, V., Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 71 (2002), 161–165.
170. [170] Ali, S.B., Moosang, M., King, L., Knight-Madden, J., Reid, M., Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol 86 (2011), 846–850.
171. [171] Cunningham-Myrie, C., Abdulkadri, A., Waugh, A., Bortolusso Ali, S., King, L.-G., Knight-Madden, J., et al. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: a cost effectiveness analysis. Pediatr Blood Cancer 62 (2015), 1862–1864.
172. [172] Ware, R.E., Helms, R.W., Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 119 (2012), 3925–3932.
173. [173] NIH ends Transcranial Doppler (TCD) with Transfusions Changing to Hydroxyurea (TWiTCH) clinical trial due to early results. Available from: http://www.nih.gov/news/health/nov2014/nhlbi-19.htm.
174. [174] Nébor, D., Romana, M., Santiago, R., Vachiery, N., Picot, J., Broquere, C., et al. Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica 98 (2013), 862–867.
175. [175] Brunetta, D.M., De Santis, G.C., Silva-Pinto, A.C., Oliveira de Oliveira, L.C., Covas, D.T., Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia. Acta Haematol 133 (2014), 287–294.
176. [176] Koc, A., Gumruk, F., Gurgey, A., The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. Pediatr Hematol Oncol 20 (2003), 429–434.
177. [177] Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339 (1998), 5–11.
178. [178] DeBaun, M.R., Gordon, M., McKinstry, R.C., Noetzel, M.J., White, D.A., Sarnaik, S.A., et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 371 (2014), 699–710.
179. [179] Miller, S.T., Wright, E., Abboud, M., Berman, B., Files, B., Scher, C.D., et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the stroke prevention trial (STOP) in sickle-cell anemia. J Pediatr 139 (2001), 785–789.
180. [180] Mahfoudhi, E., Lecluse, Y., Driss, F., Abbes, S., Flaujac, C., Garçon, L., Red cells exchanges in sickle cells disease lead to a selective reduction of erythrocytes-derived blood microparticles. Br J Haematol 156 (2012), 545–547.
181. [181] Wolters, H.J., ten Cate, H., Thomas, L.L., Brandjes, D.P., van der Ende, A., van der Heiden, Y., et al. Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?. Br J Haematol 90 (1995), 715–717.
182. [182] Schnog, J.B., Kater, A.P., Mac Gillavry, M.R., Duits, A.J., Lard, L.R., van Der Dijs, F.P., et al. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol 68 (2001), 179–183.
183. [183] Chaplin, H., Monroe, M.C., Malecek, A.C., Morgan, L.K., Michael, J., Murphy, W.A., Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 66 (1989), 574–584.
184. [184] Qari, M.H., Aljaouni, S.K., Alardawi, M.S., Fatani, H., Alsayes, F.M., Zografos, P., et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 98 (2007), 392–396.
185. [185] Matsui, N.M., Varki, A., Embury, S.H., Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 100 (2002), 3790–3796.
186. [186] Zhao, D., Ding, R., Mao, Y., Wang, L., Zhang, Z., Ma, X., Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation 35 (2012), 1825–1832.
187. [187] Sparkenbaugh, E., Pawlinski, R., Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 162 (2013), 3–14.
188. [188] Arumugam, P.I., Mullins, E.S., Shanmukhappa, S.K., Monia, B.P., Loberg, A., Shaw, M.A., et al. Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood 126 (2015), 1844–1855.
189. [189] Cabannes, R., Lonsdorfer, J., Castaigne, J.P., Ondo, A., Plassard, A., Zohoun, I., Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 15 (1984), 199–212.
190. [190] Lee, S.P., Ataga, K.I., Zayed, M., Manganello, J.M., Orringer, E.P., Phillips, D.R., et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol 139 (2007), 612–620.
191. [191] Desai, P.C., Brittain, J.E., Jones, S.K., McDonald, A., Wilson, D.R., Dominik, R., et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 132 (2013), 341–345.
192. [192] Wun, T., Soulieres, D., Frelinger, A.L., Krishnamurti, L., Novelli, E.M., Kutlar, A., et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol OncolJ Hematol Oncol, 6, 2013, 17.
193. [193] Heeney, M.M., Hoppe, C.C., Abboud, M.R., Inusa, B., Kanter, J., Ogutu, B., et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med, 2015, 10.1056/NEJMoa1512021.
194. [194] Betal, S.G., Kato, G.J., Lawrence, M.P., Seamon, C., Setty, Y., Stuart, M.J., et al. Thrombin generation in sickle cell disease: insights from computerized automated thrombography. (ASH Abstract). Blood, 114, 2009, 2587.
195. [195] Salvaggio, J.E., Arnold, C.A., Banov, C.H., Long-term anticoagulation in sickle-cell disease. N Engl J Med 269 (1963), 182–186.
196. [196] Styles, L., Heiselman, D., Heath, L.E., Moser, B.A., Small, D.S., Jakubowski, J.A., et al. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol 37 (2015), 1–9.
197. [197] Zago, M.A., Costa, F.F., Ismael, S.J., Tone, L.G., Bottura, C., Treatment of sickle cell diseases with aspirin. Acta Haematol 72 (1984), 61–64.
198. [198] Semple, M.J., Al-Hasani, S.F., Kioy, P., Savidge, G.F., A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 51 (1984), 303–306.
199. [199] Greenberg, J., Ohene-Frempong, K., Halus, J., Way, C., Schwartz, E., Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 102 (1983), 781–784.
200. [200] Osamo, N.O., Photiades, D.P., Famodu, A.A., Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 66 (1981), 102–107.
201. [201] Chaplin, H., Alkjaersig, N., Fletcher, A.P., Michael, J.M., Joist, J.H., Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 43 (1980), 218–221.